Equity ETFs Very High Risk
The investment objective of the Scheme is to provide returns before expenses that closelycorrespond to the total returns of the NIFTY Healthcare Index subject to tracking errors.
Expert-managed portfolios tailored to your financial goals.
Estimation is based on the past performance
| ETFs | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | 5.02% | 7.49% | 0.66% | -0.82% | 6.42% | 11.87% | 23.27% | 15.76% | 0% | 0% | 12.72% |
| Category returns | 10.45% | -1.93% | -3.95% | 0.33% | 4.72% | 4.18% | 14.82% | 12.21% | 13.25% | 13.57% | N/A |
| Absolute returns | 3.16% | 3.43% | 2.44% | 7.22% | 11.1% | 31.1% | 88.95% | 99.76% | 85.92% | 0% | 86.77% |
| Rank within category | 229 | 17 | 36 | 84 | 67 | 6 | 15 | 16 | 74 | 38 | N/A |
| Total Schemes in Category | 240 | 228 | 208 | 196 | 180 | 143 | 123 | 96 | 73 | 37 | N/A |
| ETFs | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Yearly returns | N/A | -10.32% | 33.48% | 40.85% | -1.84% | 5.2% |
| Q1 returns | N/A | -5.4% | -4.57% | 13.5% | -8.4% | -2.89% |
| Q2 returns | N/A | -11.31% | 17.19% | 4.2% | 5.74% | 8.34% |
| Q3 Returns | 2.36% | 9.72% | 9.14% | 17.58% | -2.06% | N/A |
| Q4 Returns | -0.13% | -2.59% | 9.37% | 1.28% | 3.47% | N/A |
Expense ratio: 0.39%
Inclusive of GST
Exit load
| Alpha | -0.0229963 |
| Beta | 0.9984 |
| Sharpe Ratio | 0.348572 |
| Sortino Ratio | 0.787068 |
| R-Squared | 0.9971 |
| Tracking Error | 0.0586 |
| Downside Risk | 16.7428 |
| Std. Deviation (Annualised) | 14.6777 |
| ETFs | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Expense Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CPSE Exchange Traded Scheme | 8.04% | 10.23% | 14.21% | 18.45% | 21.52% | 37.46% | 36.12% | 18.4% | 16.27% | 20,592.20 | 0.07 | 0.41 | Very High |
| Motilal Oswal BSE Enhanced Value ETF | 11.01% | -2.09% | 4.12% | 14.4% | 19.73% | 32.1% | 0% | 0% | 33.41% | 146.76 | 0.35 | 0.37 | Very High |
| ICICI Prudential Nifty PSU Bank ETF | 7.7% | -6.04% | 5.12% | 22.51% | 29.97% | 27.07% | 0% | 0% | 31.46% | 110.26 | 0.40 | 0.30 | Very High |
| Kotak Nifty PSU Bank ETF | 7.69% | -6.06% | 5.06% | 22.41% | 29.83% | 26.88% | 33.26% | 13.6% | 6.64% | 2,148.17 | 0.49 | 0.30 | Very High |
| Nippon India ETF Nifty PSU Bank BeES | 7.69% | -6.06% | 5.06% | 22.41% | 29.83% | 26.86% | 33.28% | 13.65% | 7.22% | 3,670.36 | 0.49 | 0.29 | Very High |
| ICICI Prudential Nifty Auto ETF | 9.02% | -2.99% | -3.3% | 9.51% | 17.11% | 25.98% | 0% | 0% | 21.22% | 162.29 | 0.20 | 0.32 | Very High |
| Nippon India Nifty Auto ETF | 9.01% | -3.01% | -3.36% | 9.44% | 17.03% | 25.89% | 0% | 0% | 22.34% | 384.16 | 0.22 | 0.32 | Very High |
| Bharat 22 ETF | 9.17% | 2.93% | 6.44% | 14.88% | 17.25% | 25.74% | 28.34% | 0% | 15.83% | 9,797.37 | 0.07 | 0.34 | Very High |
| Motilal Oswal BSE Healthcare ETF | 6.77% | 7.99% | -0.5% | -2.64% | 6% | 24.95% | 0% | 0% | 19.82% | 40.68 | 0.24 | 0.35 | Very High |
| Axis NIFTY Healthcare ETF Current | 5.02% | 7.49% | 0.66% | -0.82% | 6.42% | 23.27% | 0% | 0% | 12.72% | 20.28 | 0.34 | 0.32 | Very High |
| Instrument Allocation | Instrument | Assets % |
|---|---|---|
|
|
Domestic Equities | 99.92% |
| Cash & Cash Equivalents and Net Assets | 0.08% |
| Sector Allocation | Sector | Assets % |
|---|---|---|
| Pharmaceuticals & Biotechnology | 79.09% | |
| Healthcare Services | 20.82% | |
| Others | 0.08% |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 19.04% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.21% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.02% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 7.81% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 7.35% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.33% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.56% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 4.78% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.35% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.26% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.86% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.60% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.14% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.55% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.53% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.22% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.11% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.31% |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.00% |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 0.88% |
| Clearing Corporation of India Ltd | Cash & Cash Equivalents and Net Assets | 0.08% | |
| Net Receivables / (Payables) | Cash & Cash Equivalents and Net Assets | 0.00% | |
| Total | 100.00% |
He was earlier associated with Axis Asset Management Company Ltd (Axis AMC) where he had taken leading efforts in developing the Quantitative vertical for the AMC across platforms and was responsible for managing various funds based on quant model as well as all their Equity Passive offerings. Prior to Axis AMC, he was associated with SilverTree Hong Kong where he was responsible for portfolio management activities and managing long only &long-short funds and with Asiya Investments, Hong Kong, where he started his career as CIO, managing long only & long-short funds.
RETURNS
It is an Open ended scheme that primarily invests in ETFs.
The investment objective of the Scheme is to provide returns before expenses that closelycorrespond to the total returns of the NIFTY Healthcare Index subject to tracking errors.
The scheme benchmark is the Nifty Healthcare Index - TRI
It is classified as Very High Risk, suitable for investors with a Very High risk appetite.
Returns Delivered by the funds are as follows:
1-year: 11.1%
3-year: 23.6%
5-year: 13.2%
Top holdings include names such as:
The NAV is around ₹156.43 (approx.) for the Axis NIFTY Healthcare ETF.
The fund’s AUM is approximately ₹21 Cr.
The expense ratio for the Regular Plan is 0.39.
.
Minimum SIP starts at ₹0.
The minimum lump sum investment is ₹5000. Often platforms may require higher in practice, but the statutory minimum remains the same.
You can start a SIP through:
Broker/agent platform like Sharescart.
Enter KYC details, choose the Regular Growth option, set SIP amount/frequency, and submit.
Yes. You can modify your SIP amount or frequency anytime online through the Sharescart platform.
You can redeem online via the Sharescart platform — choose the scheme, select the amount/units, and submit. Proceeds are credited to your bank account.
The fund managers: Nandik Mallik, Rohit Gautam
This fund is suitable for investors with a Very High risk tolerance.
Get personalized Portfolio Management Services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
